Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:47:34 2024-10-14 pm EDT 		5-day change 1st Jan Change
115.90 USD +0.36% Intraday chart for Neurocrine Biosciences, Inc. +3.58% -11.83%
Oct. 04 RBC Trims Price Target on Neurocrine Biosciences to $133 From $136, Keeps Sector Perform Rating MT
Sep. 30 Neurocrine Biosciences, Inc. Announces Interim Results from the Ongoing Open-Label KINECT-HD2 Study of INGreZZA®? (valbenazine) Capsules CI

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Oct. 09
 PR
RBC Trims Price Target on Neurocrine Biosciences to $133 From $136, Keeps Sector Perform Rating
Oct. 04
 MT
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep. 30
 PR
Neurocrine Biosciences, Inc. Announces Interim Results from the Ongoing Open-Label KINECT-HD2 Study of INGreZZA®? (valbenazine) Capsules
Sep. 30
 CI
Neurocrine Biosciences, Inc. Presents at TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024, Sep-26-2024 11:00 AM
Sep. 26
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Sep. 19
 PR
Neurocrine Biosciences, Inc. Presents at 2024 Cantor Fitzgerald Global Healthcare Conference, Sep-17-2024 03:05 PM
Sep. 17
Voyager Therapeutics Says Third Gene Therapy Development Candidate Selected Under Neurocrine Collaboration
Sep. 16
 MT
Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target
Sep. 12
 MT
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Sep. 12
 PR
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Sep. 12
 CI
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Sep. 10
 PR
Neurocrine Biosciences, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 08:45 AM
Sep. 05
Neurocrine Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 03:20 PM
Sep. 04
Nxera Pharma to Receive $35M Milestone Payment for Schizophrenia Drug
Sep. 02
 MT
Nxera Pharma Co., Ltd. to Receive USD 35 Million from Neurocrine Biosciences Upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Sep. 01
 CI
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $143, Keeps Sector Perform Rating
Aug. 29
 MT
Piper Sandler Upgrades Neurocrine Biosciences to Overweight From Neutral, Adjusts PT to $159 From $131
Aug. 29
 MT
Nxera, Neurocrine Report Positive Phase 2 Results for Schizophrenia Drug
Aug. 28
 MT
Neurocrine Biosciences to Participate at Investor Conferences in September
Aug. 28
 PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.